ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen

When patients reached Ambrx Biopharma’s phase 1/2 clinical trial for prostate cancer, they were nearing the end of their treatment journey. It’s hard to read that some had gone through 13 rounds of treatment before they entered the study.